AMAG Pharmaceuticals (AMAG)
AMAG Pharmaceuticals Revenue Growth: 15.65%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMAG Revenue Growth Rankings
| Overall | 70th percentile | 1302 of 4389 |
| Sector | 63rd percentile | 166 of 460 in Healthcare |
| Industry | 82nd percentile | 3 of 17 in Diagnostic Substances |
AMAG Revenue Growth Range, Past 5 Years
| Minimum | -88.68% | Jun 2009 |
| Maximum | 34131% | Jun 2010 |
| Average | 1951% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AMAG related companies
AMAG News
AMAG (AMAG) Shares Collapse as Board Quietly Abandons Active Sale Process
May 10, 12:41PM Street Insider
May 10, 12:41PM Street Insider
Correction - Landenburg Thalmann Downgraded AMAG Pharmaceuticals (AMAG) to Hold
May 10, 8:41AM Street Insider
May 10, 8:41AM Street Insider
Baird Downgrades AMAG Pharmaceuticals (AMAG) to Neutral; Stepping To Sidelines As Risk Profile Increases
May 10, 8:06AM Street Insider
May 10, 8:06AM Street Insider
AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive Officer
May 09, 4:09PM Benzinga
May 09, 4:09PM Benzinga
Listen to $AMAG Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3bwJ
about 22 days ago by earningscast
about 22 days ago by earningscast
AMAG Pharma (AMAG) Pops Higher on Positive CHMP Opinion for Ferumoxytol
Apr 20, 9:36AM Street Insider
Apr 20, 9:36AM Street Insider
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europ
Apr 20, 9:33AM Benzinga
Apr 20, 9:33AM Benzinga
$AMAG forms bearish "Continuation Diamond" chart pattern. http://stks.co/3209
about 62 days ago by RecogniaEvents
about 62 days ago by RecogniaEvents
Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Positive IDA Trial De-Risks Major Opportunity
Mar 08, 10:02AM Street Insider
Mar 08, 10:02AM Street Insider
Listen to $AMAG Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2gGF
about 79 days ago by earningscast
about 79 days ago by earningscast
$AMAG Q4 2011 Earnings Conference Call Mar.5th at 4:30 p.m. ET. Webcast @ http://stks.co/2f03
about 81 days ago by abubnic
about 81 days ago by abubnic
$AMAG Ceo will participate at the 24th Annual ROTH Conference on Mar 13 at 4:30 pm PT. Webcast @ http://stks.co/2f00
about 81 days ago by abubnic
about 81 days ago by abubnic
$AMAG Downside Blowoff - 15 Minute Up Reversal - Green bar after 5 red bars
about 135 days ago by TradeIdeasQuant
about 135 days ago by TradeIdeasQuant
$AMAG "No serious adverse events were reported" in results of test on company's ferumoxytol
about 164 days ago by Benzinga
about 164 days ago by Benzinga
If you were patient enough to hold onto $amag through the summer/fall you are up pretty nicely
about 168 days ago by DavidSchawel
about 168 days ago by DavidSchawel
$AMAG 200 Day SMA Cross - Price crossed below 200 day SMA (16.1075). Confirmed by volume.
about 189 days ago by TradeIdeasQuant
about 189 days ago by TradeIdeasQuant
AMAG Pharmaceuticals $AMAG up 4% after hiring Jefferies to explore options, including a potential sale.
about 189 days ago by Street_Insider
about 189 days ago by Street_Insider
15 breakouts: $AMAG (200-day MA + gap + base), $MXWL (stop: $17.99), $MDAS (gap). Two sub-$1. Okay mix of stocks if some are extended.
about 199 days ago by fallondpicks
about 199 days ago by fallondpicks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMAG | 13.22 | +0.02 | +0.15% | 279.84M |
| ALX | 386.74 | -2.04 | -0.52% | 1.987B |
| ALVR | 0.485 | -0.01 | -3.00% | 28.12M |
| ALV | 57.69 | +0.48 | +0.84% | 5.121B |
| ALU | 1.56 | +0.08 | +5.41% | 3.442B |
